Nivolumab and Ipilimumab Combination Therapy for Second-Line Treatment of Hepatocellular Carcinoma

MLA

Fadi, Braiteh. “Nivolumab and Ipilimumab Combination Therapy for Second-Line Treatment of Hepatocellular Carcinoma.” Gastroenterologyhepatology, vol. 17, no. 2, May 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........041c28b5c4ad33f52e6e6996aebc8840&authtype=sso&custid=ns315887.

APA

Fadi, B. (2021). Nivolumab and Ipilimumab Combination Therapy for Second-Line Treatment of Hepatocellular Carcinoma. Gastroenterologyhepatology, 17(2).

Chicago

Fadi, Braiteh. 2021. “Nivolumab and Ipilimumab Combination Therapy for Second-Line Treatment of Hepatocellular Carcinoma.” Gastroenterologyhepatology 17 (2). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........041c28b5c4ad33f52e6e6996aebc8840&authtype=sso&custid=ns315887.